Investigational drug · Phase 2
FF-10832
Also called: Gemcitabine Liposome
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
23
Any phase or sponsor naming "FF-10832"
First trial start
2022
Jun 1, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FF-10832", any sponsor or status.
- Phase 217
Conditions studied
As listed on its trial records.
- Advanced Urothelial Carcinoma
- Advanced Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Bladder and urothelial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "FF-10832" as an intervention, largest first.
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00942331 · 506 participants · Start Jul 15, 2009 · Primary completion Nov 2, 2018
Drug: Bevacizumab; Cisplatin and 1 more · For: Advanced Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Prostate Carcinoma and 10 more
Sites: Birmingham, Alabama; Mobile, Alabama; Fairbanks, Alaska · 873 sites in all
- Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder CancerPivotal-lookingActive, not recruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04559139 · 186 participants (planned) · Start Feb 24, 2021 · Primary completion Jul 1, 2028
Drug: Cisplatin; Gemcitabine Hydrochloride · For: Stage II Gallbladder Cancer AJCC v8; Stage IIA Gallbladder Cancer AJCC v8; Stage IIB Gallbladder Cancer AJCC v8 and 3 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 367 sites in all
- Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has SpreadPivotal-lookingActive, not recruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04233866 · 176 participants · Start Aug 26, 2020 · Primary completion Mar 2, 2026
Drug: Fluorouracil; Gemcitabine and 5 more · For: Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 760 sites in all
- A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung CancerPivotal-lookingActive, not recruiting
Fujifilm Pharmaceuticals U.S.A., Inc.Industry
NCT05318573 · 120 participants (planned) · Start Jun 1, 2022 · Primary completion May 2029
Drug: Pembrolizumab; FF-10832 · For: Advanced Urothelial Carcinoma; Advanced Non Small Cell Lung Cancer
Sites: Long Beach, California; San Diego, California; Washington D.C., District of Columbia · 23 sites in all
UNC Lineberger Comprehensive Cancer CenterAcademic, hospital or other
NCT06483555 · 104 participants (planned) · Start Feb 6, 2025 · Primary completion Aug 2027
Drug: Gemcitabine; Nab paclitaxel and 3 more · For: Pancreatic Adenocarcinoma; Metastatic Pancreatic Cancer; Basal Cell Neoplasm
Sites: Chapel Hill, North Carolina
Northwestern UniversityAcademic, hospital or other
NCT05733000 · 94 participants (planned) · Start Mar 8, 2023 · Primary completion Jan 4, 2028
Drug: Devimistat; Fluorouracil and 2 more · For: Advanced Biliary Tract Carcinoma; Advanced Colorectal Carcinoma; Advanced Gastroesophageal Junction Adenocarcinoma and 30 more
Sites: Chicago, Illinois
- A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract CancerActive, not recruiting
Fujifilm Pharmaceuticals U.S.A., Inc.Industry
NCT03440450 · 90 participants · Start Mar 22, 2018 · Primary completion Oct 2026
Drug: FF-10832 Gemcitabine Liposome Injection · For: Advanced Solid Tumors; Biliary Tract Cancer
Sites: Scottsdale, Arizona; Tucson, Arizona; Newport Beach, California · 7 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02506959 · 83 participants · Start Sep 14, 2015 · Primary completion Jun 3, 2024
Drug: Busulfan; Gemcitabine Hydrochloride and 2 more · For: Plasma Cell Leukemia; Plasmacytoma; Recurrent Plasma Cell Myeloma and 1 more
Sites: Houston, Texas
- Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by SurgeryActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02420847 · 57 participants (planned) · Start Jul 3, 2015 · Primary completion Dec 31, 2025
Drug: Doxorubicin Hydrochloride; Gemcitabine Hydrochloride and 1 more · For: Metastatic Urothelial Carcinoma; Transitional Cell Carcinoma; Unresectable Transitional Cell Carcinoma
Sites: Houston, Texas
Gynecologic Oncology GroupResearch network
NCT01595061 · 57 participants · Start Jul 2, 2012 · Primary completion Sep 23, 2020
Drug: Cisplatin; Gemcitabine Hydrochloride · For: Stage III Vulvar Cancer AJCC v7; Stage IIIA Vulvar Cancer AJCC v7; Stage IIIB Vulvar Cancer AJCC v7 and 3 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Burbank, California · 193 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A physiologically based pharmacokinetic and pharmacodynamic model for disposition of FF-10832.
Matsumoto T, Masuo Y, Tanaka A, et al. · Int J Pharm 2022
- A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
Matsumoto T, Komori T, Yoshino Y, et al. · Pharm Res 2021
- FF-10832 enables long survival via effective gemcitabine accumulation in a lethal murine peritoneal dissemination model.
Higuchi T, Yokobori T, Takahashi R, et al. · Cancer Sci 2019
- Analysis of gemcitabine liposome injection by HPLC with evaporative light scattering detection.
Zhou Q, Liu L, Zhang D, et al. · J Liposome Res 2012
- Preparation and characterization of gemcitabine liposome injections.
Zhou Q, Liu L, Zhang D, et al. · Pharmazie 2012
Also in development for Advanced Urothelial Carcinoma
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- SYS6002Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.